[{"title":"Calithera Biosciences, Inc. (CALA) Q1 2019 Earnings Call Transcript","callText":"\n                                            \n                                                \nImage source: The Motley Fool.\n\nCalithera Biosciences, Inc. (NASDAQ:CALA) Q1 2019 Earnings Call May 9, 2019, 5:00 p.m. ET\nContents:\n\nPrepared Remarks\nQuestions and Answers\nCall Participants\n\nPrepared Remarks:\nOperator\nHello, and welcome to the Calithera Biosciences Q1 2019 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. If anyone should require assistance during the conference, please press *0 on your touchtone telephone. I would now like to introduce your host for today's call, Jennifer McNealy. You may begin.\nJennifer McNealy -- Vice President of Investor Relations and Strategy\nThank you, Towanda. Good afternoon, everyone. Welcome to our first quarter 2019 conference call. Joining me today are Susan Molineaux, our Founder, President, and CEO, Keith Orford, Chief Medical Officer, and Stephanie Wong, Senior Vice President of Finance. We have issued our press release, and it can be accessed through our website at calithera.com.\nBefore we begin, I would like to remind you that today's discussion will include statements about our future expectations, plans, and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risk factors discussed in the Risk Factors section of our quarterly report on Form 10-Q, filed with the SEC.\n\nIn addition, any forward-looking statements represent our views only as of today, and should not be implied as representing our views on any subsequent dates. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Please note that this call is being record. With that, I'll turn the call over to Susan.\nSusan Molineaux -- Founder, President, and Chief Executive Officer\nThanks, Jennifer, and good afternoon, everyone. Thank you for joining us today on our first quarter 2019 conference call. At Calithera, we are building an integrated biotechnology company that develops novel small-molecule onco-metabolism drugs, drugs that are targeting tumor and immune cell metabolism pathways for the treatment of cancer and other diseases. By building a pipeline of novel therapeutic product candidates, we are creating multiple opportunities to positively impact clinical outcomes for patients and drive development programs toward commercialization.\nThis year, we expect to achieve multiple key milestones in our clinical development program and have several data readouts, including top-line results of the ENTRATA trial midyear, and with our partner Insight, data from the 1158 program in the second half of the year. In the first quarter, we've also made great strides in our earlier-stage programs, advancing our cystic fibrosis program into the clinic and presenting preclinical data on our CD73 inhibitor, which is poised to enter the clinic by year end.\nWe continue to advance our program for telaglenastat, also known as CB-839, for the treatment of renal cell carcinoma, or RCC, and in parallel, we are conducting earlier-stage clinical studies outside of RCC. We completed enrollment of the randomized ENTRATA trial, comparing the combination of telaglenastat plus everolimus versus placebo plus everolimus for the treatment of patients with late-stage RCC. We also continue to enroll our global randomized CANTATA trial, comparing the randomization of telaglenastat plus cabozantinib versus placebo plus cabozantinib in earlier-stage patients with RCC. And, we broadened our clinical development program for telaglenastat to two new clinical trial collaborations with Pfizer.\nOur internal discovery team continues to produce novel drug candidates with the potential to be highly differentiated new therapies in areas of unmet need. Our two new internally discovered, novel, small-molecule drug candidates are both entering clinical development in 2019. The first one is CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis, which is already in Phase 1 study, and the second one is CB-708, an oral small-molecule CD73 inhibitor for the treatment of cancer.\nAs our programs move forward in development, we look forward to a number of important milestones in 2019. For telaglenastat, the ENTRATA trial is fully enrolled, and we expect to report top-line data in mid-2019, and we also plan to enroll the CANTATA trial, a Phase 2 randomized trial with approximately 400 patients, by year end. For 1158, we and our partner Insight expect to present data at a medical meeting in the second half of 2019. For CB-280, we achieved our goal of initiating a Phase 1 trial in the first quarter of 2019 and look forward to additional updates on this program. And, for CB-708, at AACR, we presented preclinical abstract data describing CB-708. We believe there is increasing interest among the scientific community in the adenosine pathways, and we expect to initiate a Phase 1 trial in 2019. And, with that, I will pass the call over to Keith for an update on clinical progress.\nKeith Orford -- Chief Medical Officer\nThank you, Susan. Let's begin with a more detailed update on telaglenastat, our glutaminase inhibitor and our most advanced product candidate. We are currently focused on forging a clinical commercial path for telaglenastat in renal cell carcinoma. The program includes two randomized clinical trials of telaglenastat for the treatment of RCC. The Phase 2 ENTRATA trial of telaglenastat in combination with everolimus in late-line patients recently completed enrollment.\nThis randomized, double-blind trial, which is designed to evaluate the efficacy and safety of telaglenastat in combination with everolimus, enrolled 69 late-line clear-cell RCC patients who had previously been treated with at least two prior lines of systemic therapy, including a VEGF-receptor-targeted tyrosine kinase inhibitor. Patients are being randomized in a 2-to-1 ratio to either telaglenastat plus everolimus or placebo plus everolimus. The primary endpoint is progression-free survival. Overall survival will be assessed as a secondary endpoint. The multicenter study is being conducted at sites in the United States. We anticipate we will reach the primary endpoint analysis and report top-line results, including key safety and efficacy data, in mid-2019.\nWe are also actively enrolling CANTATA, the global trial of telaglenastat in combination with cabozantinib, in second- and third-line RCC patients. CANTATA is a randomized single-control trial in approximately 400 patients, and has registration potential. It is designed to evaluate the efficacy and safety of telaglenastat in combination with cabozantinib versus placebo plus cabozantinib in clear-cell RCC patients who have previously received one or two prior lines of therapy, including at least one prior anti-androgenic agent or the ipilimumab/nivolumab combination.\nPatients are being randomized in a 1-to-1 ratio to either telaglenastat plus cabozantinib or placebo plus cabozantinib. Patients will be stratified by INVC risk category and prior treatment with anti-PD1/PDL1 therapy. The primary endpoint is progression-free survival by independent review. Overall survival will be assessed as a key secondary endpoint. We believe our oral presentation at the 2019 ASCO GU meeting in February, in which we demonstrated a 50% response rate among 10 clear-cell patients, provides strong scientific rationale for the CANTATA trial.\nLate last year, we announced two new clinical trial collaborations to evaluate Pfizer's CDK4/6 inhibitor palbociclib, also known as Ibrance, and the PARP inhibitor talazoparib, also known as Talzenna, each in combination with Calithera's glutaminase inhibitor telaglenastat. Preclinical data suggests that telaglenastat synergizes with PARP inhibitors to impair DNA synthesis, enhance DNA damage, and block cancer cell proliferation.\nWe recently initiated a Phase 1/2 clinical trial with a combination of telaglenastat plus talazoparib in patients with RCC and TNBC. The trial will evaluate the potential of telaglenastat to sensitize tumors to talazoparib in patients regardless of mutations in the BRCA gene. Telaglenastat also synergizes with CDK4/6 inhibitors by enhancing cell cycle arrest and blocking cancer cell proliferation. This quarter, we plan to initiate a Phase 1/2 clinical trial of the combination of telaglenastat plus palbociclib in patients with KRAS-mutated colorectal cancer, or CRC, and patients with KRAS-mutated non-small-cell lung cancer, or NSCLC.\nNext, the arginase program: INCB001158, also known as 1158, is an investigational first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, an immunosuppressive enzyme secreted by myeloid-derived suppressor cells, or MDSCs, to block T cell activation in tumors. 1158 is being developed with Insight in a co-development co-commercialization collaboration. The program is progressing well and is actively enrolling two 1158 trials. The first trial is evaluating 1158 as a monotherapy and in combination with pembrolizumab. The second trial is evaluating 1158 in combination with each of three chemotherapy regimens: FOLFOX, gemcitabine cisplatin, or paclitaxel. Primary endpoints include safety and objective response rate. We and our partner Insight plan to present solid tumor data at a medical meeting in the second half of 2019.\nCB-280 is a novel arginase inhibitor in development for the treatment of cystic fibrosis. Under our collaboration agreement with Insight, we retain worldwide rights to develop arginase inhibitors in specific non-oncology rare disease indications, including cystic fibrosis. Arginase has been proposed to be critical in the pathophysiology of cystic fibrosis and several other non-oncology diseases. CF patients have neutrophil infiltrates in their lungs, and these neutrophils secrete high levels of arginase. Higher arginase activity depletes arginine, which in turn depletes nitric oxide. Nitric oxide, or NO, is known to have potent antimicrobial activity and has been shown to improve lung function when administered to CF patients.\nWe have hypothesized that inhibition of arginase with CB-280 can restore normal arginine and NO levels and improve lung function in CF patients. In February, we announced that we filed an IND application for CB-280 with the U.S. FDA and initiated a Phase 1 clinical trial. This first-in-human Phase 1 trial, which we plan to complete this year, is evaluating the safety, tolerability, and pharmacokinetic profile of oral CB-280 in healthy volunteers.\nOur next onco-metabolism drug candidate is CB-708, an orally bioavailable small-molecule inhibitor of CD73, an enzyme in the immunosuppressive adenosine pathway. CD73 suppresses immune activation by converting extracellular ATP into adenosine. CB-280, a potent oral inhibitor of CD73, has both single-agent activity and activity in combination with NTPD1 and standard chemotherapy in preclinical animal models. We plan to initiate clinical studies with CB-280 in 2019. And, with that, I'll pass it over to Stephanie for an update on our financials.\nStephanie Wong -- Senior Vice President of Finance\nThank you, Keith, and good afternoon, everyone. Detailed financial results for the first quarter 2019 were included in today's press release. I will briefly review our results on this call. Calithera ended the quarter well capitalized, which enables us to drive our clinical programs to meaningful value inflection points. Cash and investments were $117 million at March 31, 2019. R&D expenses were $20.2 million for the quarter compared with $15.5 million prior year. The increase of $4.7 million was primarily due to a $2.3 million in the telaglenastat program, including our Phase 2 CANTATA trial, an increase of $1.1 million in the 1158 program, an increase of $1.0 million in the CB-280 program, as well as an investment in early stage research.\nDNA expenses were $4.2 million for the quarter compared with $3.5 million prior year. The increase of $0.7 million was related to higher personnel-related costs and professional services costs. Net loss from operations for the three months ended March 31, 2019 was $23.7 million, or $0.61 per share. And with that, I will now return the call back over to Susan.\nSusan Molineaux -- Founder, President, and Chief Executive Officer\nThank you, Stephanie. With that, operator, we're happy to open the line for questions.\nQuestions and Answers:\nOperator\nThank you. Ladies and gentlemen, if you'd like to ask a question at this time, please press *1 on your touchtone telephone. That's *1 if you'd like to ask a question. Our first question comes from the line of Jonathan Chang with SVB Leerink. Your line is open.\nJohn Barrett -- SVB Leerink -- Analyst\nHello. This is John Barrett on for Jonathan. Could you provide any additional color on the updated timing for ENTRATA?\nKeith Orford -- Chief Medical Officer\nSure. So, as you've noticed, we've updated the guidance to mid-2019, which is really -- given that we're farther along, we have more information, we're able to just narrow that timing down from our original guidance. So, no significant change, just really a narrowing of the guidance.\nJohn Barrett -- SVB Leerink -- Analyst\nGot it. How should we be thinking about the implications of ENTRATA data that you're now expecting in mid-2019 on the CANTATA study?\nKeith Orford -- Chief Medical Officer\nSo, ENTRATA, as we've mentioned, is a randomized study. Our first randomized study will be our first randomized data in RCC patients, and it's in combination with everolimus. It will be -- and, as you know, CANTATA study is also in RCC, so it'll be our first data in RCC patients. There are differences and there are similarities between the two. We have preclinical data that suggests similar mechanisms of synergy, but obviously, the design of the study is different enough in terms of patient population and line of therapy that a direct readthrough is not obvious, but... I'll leave it there.\nJohn Barrett -- SVB Leerink -- Analyst\nGreat, thanks for the color. One more, if I may. How are you thinking about the adenosine landscape post the recent data announcements from some competitors in the space?\nKeith Orford -- Chief Medical Officer\nAt AACR, there was some encouraging data for the A2A receptor inhibitors, and particularly in the prostate cancer space. So, we saw that as very positive for the mechanism and for the pathway, and we maintain our enthusiasm, and we think the rest of the field maintains considerable enthusiasm for the adenosine pathway.\nJohn Barrett -- SVB Leerink -- Analyst\nGreat. Thanks for answering my questions, and good luck.\nKeith Orford -- Chief Medical Officer\nThank you.\nOperator\nThank you. Our next question comes from the line of Matt Phipps with William Blair. Your line is open.\nMatthew Phipps -- William Blair -- Analyst\nHey, good afternoon. Thanks for taking my questions. Let's follow up on the adenosine a little bit. Is this something where you think you would try to accelerate development specifically in prostate cancer or renal cell, where we've seen monotherapy activity with the A2A inhibitors? And then, is there any reason to think that CD73 inhibition would not -- maybe a different expression would be not correlated as far as seeing responses as far as the A2A receptors as far as tumor types go?\nKeith Orford -- Chief Medical Officer\nSo, I think we definitely -- part of the benefit of not being first in class here is that we're able to learn from the folks that are in front of us. So, we think we have the best-in-class molecule that's orally bioavailable and can provide continuous inhibition of the pathway, and we can learn from those that are in front of us. So, absolutely, we would expect to be able to increase the efficiency of development through learning from the other programs that are in front of us. In terms of differences between CD73 and A2A receptor inhibition, we expect there to be a lot of overlap there in terms of where one would expect to see activity, but we can't assume 100% correlation between them. But, certainly, activity that we see in that pathway is likely to be worth following up on.\nMatthew Phipps -- William Blair -- Analyst\nThanks, Keith. And then, additionally, do you think there's an added benefit by inhibiting both CD73 and A2A receptors? There are a number of those combination trials ongoing.\nKeith Orford -- Chief Medical Officer\nI think there's a diversity of opinions on that. I can certainly see the rationale, particularly given some of the characteristics of the pathway inhibitors that exist. There may be utility in hitting that pathway twice to ensure full inhibition. On the other hand, one could imagine that a more potent or maybe more active molecule might make it unnecessary to hit that pathway vertically. So, I think it remains an open question, and one that is certainly still being debated, and you can see based on different sponsors' approaches to vertical inhibition that there isn't a uniformity or consensus around that at this point.\nMatthew Phipps -- William Blair -- Analyst\nGot it, OK. And then, lastly, for the CB-280, did we get biomarker or PK/PD data from healthy volunteers this year, and are you planning on initiating the CF patient trial this year as well? How quickly are these trials...?\nKeith Orford -- Chief Medical Officer\nSo, as you know, with the dose escalation, the timing is hard to nail down precisely given that we have...a certain number of dose levels planned, but you never know exactly how the timing will play out. So, we do expect to be able to get that study completed this year, and we certainly will have access to PK and some amount of PD data. I think PD -- it should be noted that PD in a healthy volunteer population is going to be different from a patient population, so a clear interpretation of that is -- we'll see what we see when we generate the data. In terms of the timeline, I think we do expect to complete that study this year, and then, the plan would be to move forward with the patient study soon after.\nMatthew Phipps -- William Blair -- Analyst\nAnd, as far as then dosing to try to get to your recommended dose, is it something where you're actually going to look for...urea cycle disruption? I'm sorry, I can't remember exactly what it was from the other arginase program.\nKeith Orford -- Chief Medical Officer\nThe orotic acid?\nMatthew Phipps -- William Blair -- Analyst\nYeah, sorry. Thanks.\nKeith Orford -- Chief Medical Officer\nWe'll certainly be monitoring that. As you know, orotic acid is a very early sign that we're starting to impact the urea cycle, although the reason to follow it is that we can see that elevation well before a clinically significant inhibition of the urea cycle, but we do plan on following that as well, and that would inform dose selection to some extent, yes.\nMatthew Phipps -- William Blair -- Analyst\nAll right, great. Thanks, and good luck.\nKeith Orford -- Chief Medical Officer\nThanks, Matt.\nOperator\nI'm showing no further questions at this time. I would now like to turn the call back over to Jennifer McNealy for closing remarks.\nJennifer McNealy -- Vice President of Investor Relations and Strategy\nThank you, Towanda, and thanks, all, for joining us today. Have a good evening.\nOperator\nLadies and gentlemen, that concludes today's conference. Thank you for participating. You may now disconnect. Everyone have a wonderful day.\nDuration: 23 minutes\nCall participants:\nJennifer McNealy -- Vice President of Investor Relations and Strategy\nSusan Molineaux -- Founder, President, and Chief Executive Officer\nKeith Orford -- Chief Medical Officer\nStephanie Wong -- Senior Vice President of Finance\nJohn Barrett -- SVB Leerink -- Analyst\nMatthew Phipps -- William Blair -- Analyst\nMore CALA analysis\nThis article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and ConditionsÂ for additional details, including our Obligatory Capitalized Disclaimers of Liability.\n10 stocks we like better than Calithera BiosciencesWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*\nDavid and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Calithera Biosciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.\nSee the 10 stocks\n*Stock Advisor returns as of March 1, 2019\n                                            \n                                        "}]